<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624294</url>
  </required_header>
  <id_info>
    <org_study_id>CS0159-001A</org_study_id>
    <nct_id>NCT05624294</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Does/ Mulelple Ascending Does Study of CS0159 to Evaluate the Safety, Tolerability, Pharmacokynetics, and Food Effect in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cascade Pharmaceuticals, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cascade Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I clinical bridging trial, randomized, double-blind, placebo-controlled,&#xD;
      single ascending does/ mulelple ascending does study of CS0159 to evaluate the safety,&#xD;
      tolerability, pharmacokynetics, pharmacodynamices, and food effect in Chinese healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2022</start_date>
  <completion_date type="Actual">March 28, 2023</completion_date>
  <primary_completion_date type="Actual">March 28, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events [Safety and Tolerability]</measure>
    <time_frame>Upto day 15</time_frame>
    <description>Occurrence of Serious Adverse Event (SAE), Adverse Event (AE) resulting in treatment discontinuation, and AE of special interest, from baseline up to 15 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose PK Parameter(C-max)</measure>
    <time_frame>day 1, day 7</time_frame>
    <description>Evaluate the Peak Plasma Concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose PK Parameter(AUC)</measure>
    <time_frame>day 1, day 7</time_frame>
    <description>Evaluate the Area under the plasma concentration versus time curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Food effect PK Parameter(C-max)</measure>
    <time_frame>day 10</time_frame>
    <description>Evaluate the Peak Plasma Concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect PK Parameter(AUC)</measure>
    <time_frame>day 10</time_frame>
    <description>Evaluate the Area under the plasma concentration versus time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc analysis</measure>
    <time_frame>day 1, day 7</time_frame>
    <description>analysize the plasma Concentration relevance to QTcF</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>2mg CS0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet daily for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg CS0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablet daily for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6mg CS0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three tablet daily for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS0159</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>2mg CS0159</arm_group_label>
    <arm_group_label>4mg CS0159</arm_group_label>
    <arm_group_label>6mg CS0159</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>2mg CS0159</arm_group_label>
    <arm_group_label>4mg CS0159</arm_group_label>
    <arm_group_label>6mg CS0159</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult subjects of 18 years to 55 years.&#xD;
&#xD;
          2. Weight: Male≥50kg, female≥45kg BMI: 18~32kg/m².&#xD;
&#xD;
          3. In good health, determined by having no clinically significant findings from medical&#xD;
             history, physical examination, 12-lead ECG, vital signs measurements, and clinical&#xD;
             laboratory evaluation.&#xD;
&#xD;
          4. Subject signs IFC and dates and subject must understand and follow test procedures and&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with special dietary requirements and cannot follow a uniform diet.&#xD;
&#xD;
          2. Pregnant or nursing females or females who have pregnancy plans during the trial or&#xD;
             within 3 months after the trial.&#xD;
&#xD;
          3. Any subject with SARS-CoV-2 infection, based on a positive polymerase chain reaction&#xD;
             for SARS-CoV-2.&#xD;
&#xD;
          4. History or evidence of clinically significant disorder, condition, or disease that, in&#xD;
             the opinion of the investigator, would pose a risk to subject safety or interfere with&#xD;
             the study evaluations, procedures, or completion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Xuhui Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>April 29, 2023</last_update_submitted>
  <last_update_submitted_qc>April 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

